+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Spinocerebellar Ataxia (SCA) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767828
  • Report
  • April 2019
  • Region: Global
  • 81 pages
  • VPA Research

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Baxter International Inc
  • Bio Blast Pharma Ltd
  • Cadent Therapeutics
  • Cognitive Research Corp
  • Cytel Inc
The global clinical trial report- “2019 Spinocerebellar Ataxia (SCA) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Spinocerebellar Ataxia (SCA). It presents in-depth analysis of Spinocerebellar Ataxia (SCA) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Spinocerebellar Ataxia (SCA).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Spinocerebellar Ataxia (SCA) clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Spinocerebellar Ataxia (SCA)

The research work is prepared through extensive and continuous research on Spinocerebellar Ataxia (SCA) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Spinocerebellar Ataxia (SCA) patients are identified
  • The report includes panorama of Spinocerebellar Ataxia (SCA) clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Spinocerebellar Ataxia (SCA) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Baxter International Inc
  • Bio Blast Pharma Ltd
  • Cadent Therapeutics
  • Cognitive Research Corp
  • Cytel Inc
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Spinocerebellar Ataxia (SCA) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Spinocerebellar Ataxia (SCA) Clinical Trials by Region
2.2.2 Average Enrollment of Spinocerebellar Ataxia (SCA) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Spinocerebellar Ataxia (SCA) Treatment, 2019

3. Region wise Spinocerebellar Ataxia (SCA) Clinical Trials
3.1 Asia Pacific Spinocerebellar Ataxia (SCA) Clinical Trials by Country
3.2 Europe Spinocerebellar Ataxia (SCA) Clinical Trials by Country
3.3 North America Spinocerebellar Ataxia (SCA) Clinical Trials by Country
3.4 Middle East and Africa Spinocerebellar Ataxia (SCA) Clinical Trials by Country
3.5 South and Central America Spinocerebellar Ataxia (SCA) Clinical Trials by Country

4. Spinocerebellar Ataxia (SCA) Clinical Trial Trends
4.1 Start Year wise Spinocerebellar Ataxia (SCA) Clinical Trials
4.2 Phase wise Spinocerebellar Ataxia (SCA) Clinical Trials
4.3 Trial Status wise Spinocerebellar Ataxia (SCA) Clinical Trials
4.4 Trial Type wise Spinocerebellar Ataxia (SCA) Clinical Trials

5. Spinocerebellar Ataxia (SCA) Average Enrollment Trends
5.1 Average Enrollment in Spinocerebellar Ataxia (SCA) Trials by Year
5.2 Average Enrollment in Spinocerebellar Ataxia (SCA) Trials by Phase
5.3 Average Enrollment in Spinocerebellar Ataxia (SCA) Trials by Status
5.4 Average Enrollment in Spinocerebellar Ataxia (SCA) Trials by Type of Trial

6. Companies Participating in Spinocerebellar Ataxia (SCA) Clinical Trials
6.1 Spinocerebellar Ataxia (SCA) Trials by Sponsor Type
6.2 Spinocerebellar Ataxia (SCA) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Spinocerebellar Ataxia (SCA) Trials- Phase 1
7.2 Spinocerebellar Ataxia (SCA) Trials- Phase 2
7.3 Spinocerebellar Ataxia (SCA) Trials- Phase 3
7.4 Spinocerebellar Ataxia (SCA) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Spinocerebellar Ataxia (SCA) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Figure 5: Europe - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Figure 7: North America - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Figure 9: Spinocerebellar Ataxia (SCA) Clinical Trials by Phase
Figure 10: Spinocerebellar Ataxia (SCA) Clinical Trials by Trial Status
Figure 11: Spinocerebellar Ataxia (SCA) Clinical Trials by Type
Figure 12: Spinocerebellar Ataxia (SCA) Clinical Trials by Sponsor Type
Figure 13: Spinocerebellar Ataxia (SCA) Clinical Trials by Leading Sponsors
Figure 14: Spinocerebellar Ataxia (SCA) Average Enrollment by Phase
Figure 15: Spinocerebellar Ataxia (SCA) Average Enrollment by Trial Status
Figure 16: Spinocerebellar Ataxia (SCA) Average Enrollment by Type
Figure 17: Spinocerebellar Ataxia (SCA)- Average Enrolment by Type of Sponsors
Figure 18: Spinocerebellar Ataxia (SCA)- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Spinocerebellar Ataxia (SCA) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Table 5: Europe - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Table 7: North America - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Spinocerebellar Ataxia (SCA) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Spinocerebellar Ataxia (SCA) Average Enrollment by Phase
Table 15: Spinocerebellar Ataxia (SCA) Average Enrollment by Trial Status
Table 16: Spinocerebellar Ataxia (SCA) Average Enrollment by Type
Table 17: Spinocerebellar Ataxia (SCA)- Average Enrolment by Type of Sponsors
Table 18: Spinocerebellar Ataxia (SCA)- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
  • Acorda Therapeutics Inc
  • Baxter International Inc
  • Bio Blast Pharma Ltd
  • Cadent Therapeutics
  • Cognitive Research Corp
  • Cytel Inc
  • Daiichi Sankyo Co Ltd
  • Kissei Pharmaceutical Co Ltd
  • Pamplona Capital Management LLP
  • Portage Biotech Inc
Note: Product cover images may vary from those shown
Adroll
adroll